Yale University School of Medicine, New Haven, CT, United States of America.
Department of Community Medicine and Health Care, School of Medicine, University of Connecticut, Farmington, CT, USA; Department of Psychiatry, School of Medicine, Yale University, New Haven, CT, USA; Center for Outcomes Research and Evaluation (CORE), Yale-New Haven Health System, New Haven, CT, USA.
Prev Med. 2019 Jun;123:123-129. doi: 10.1016/j.ypmed.2019.03.022. Epub 2019 Mar 17.
The United States is currently facing an epidemic of opioid-related deaths, increasingly associated with fentanyl use. Our objective was to characterize rates of fentanyl, general opioid and non-opioid pain medication prescription at a national level in both outpatient and emergency department settings. We used a retrospective cross-sectional research design using data from the 2006-2015 National Ambulatory Medical Care Surveys and National Hospital Ambulatory Medical Care Surveys. Between 2006-2015, 66,987 (17.4%) of 390,538 office-based outpatient visits (nationally-representative of 961 million visits) and 134,953 (45.0%) of 305,570 ED visits (nationally-representative of 130 million visits) listed a pain medication prescription. The proportion of all outpatient visits in which any pain medication was prescribed increased from 15.0% in 2006-2007 to 20.5% in 2014-2015 (p < 0.001). The proportion of all outpatient visits in which any fentanyl product was prescribed remained stable at 0.3% and 0.4% (p = 0.32), but increased among ED visits from 0.5% to 1.1% (p = 0.006). In contrast, the proportion of all outpatient visits in which any opioid product was prescribed increased from 6.6% to 9.7% (p < 0.001), but remained relatively stable among ED visits from 26.2% to 24.4% (p = 0.07). Non-opioid pain medication prescription increased in both settings, from 9.7% to 13.7% (p < 0.001) in the outpatient setting and from 25.6% to 27.6% (p = 0.02) in the ED setting between 2006-2007 and 2014-2015, respectively. To address current opioid crisis, both clinical and public health interventions are needed, such as targeted education outreach on evidence-based opioid prescribing and non-opioid alternatives.
美国目前正面临阿片类药物相关死亡的流行,与芬太尼的使用日益相关。我们的目的是在全国范围内的门诊和急诊环境中描述阿片类药物、一般阿片类药物和非阿片类药物止痛药物的处方率。我们使用回顾性横断面研究设计,使用 2006-2015 年全国门诊医疗保健调查和全国医院门诊医疗保健调查的数据。在 2006-2015 年期间,390538 次门诊就诊中有 66987 次(占 17.4%)(全国 9.61 亿次就诊的代表性样本)和 134953 次(占 45.0%)急诊就诊中有 305570 次(全国 1.3 亿次就诊的代表性样本)列出了止痛药物处方。所有门诊就诊中开具任何止痛药物的比例从 2006-2007 年的 15.0%增加到 2014-2015 年的 20.5%(p<0.001)。所有门诊就诊中开具任何芬太尼产品的比例保持在 0.3%和 0.4%(p=0.32),但急诊就诊中从 0.5%增加到 1.1%(p=0.006)。相比之下,所有门诊就诊中开具任何阿片类药物产品的比例从 6.6%增加到 9.7%(p<0.001),但急诊就诊中从 26.2%增加到 24.4%(p=0.07)保持相对稳定。在这两个环境中,非阿片类止痛药物的处方都有所增加,从 2006-2007 年的 9.7%增加到 2014-2015 年的 13.7%(p<0.001),从 25.6%增加到 27.6%(p=0.02)。为了解决当前的阿片类药物危机,需要采取临床和公共卫生干预措施,例如有针对性的教育宣传,宣传基于证据的阿片类药物处方和非阿片类药物替代品。